莱斯康制药 LXRX 深 沪
已收盘 12-19 16:00:00 美东时间
1.17
-0.010
-0.85%
华盛通- 最 高1.4799
- 今 开1.17
- 成交量 330.01万股
- 最 低 1.115
- 昨 收 1.18
- 总市值 1.76亿
- 52周最高 1.66
- 市盈率 静 --
- 换手率 2.20%
- 52周最低 0.2836
- 委 比 12.50%
- 总股本 1.50亿
- 历史最高 22.96
- 量 比 2.08
- 振 幅 30.92%
- 历史最低 0.00
- 每 手 1
- 风险率 0.35%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Earnings Scheduled For November 6, 2025
Companies Reporting Before The Bell • Clear Channel Outdoor (NYSE:CCO) is expec...
11-06 19:12
Lexicon to Present Data at the 85th Scientific Sessions of the American Diabetes Association (ADA)
Lexicon Pharmaceuticals will present data on sotagliflozin's ability to reduce hypoglycemia risk in type 1 diabetes across kidney function levels during the ADA's 85th Scientific Sessions. The company will also share topline results from the PROGRESS Phase 2b study evaluating pilavapadin for diabetic peripheral neuropathic pain. Sotagliflozin is an SGLT2/SGLT1 inhibitor, and pilavapadin is an oral, non-opioid AAK1 inhibitor.
06-18 12:30
Lexicon Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference
Lexicon Pharmaceuticals announced its management will participate in a fireside chat at the 2025 Jefferies Global Healthcare Conference on June 5, 2025, in New York City. The event can be accessed via the company's website, and a replay will be available afterward. Lexicon, a biopharmaceutical company focused on innovative medicines, has advanced multiple therapies and has a strong pipeline across various disease areas.
05-29 12:00
What Analysts Are Saying About Lexicon Pharmaceuticals Stock
Lexicon Pharmaceuticals (NASDAQ:LXRX) has been analyzed by 4 analysts in the la...
03-07 21:00
Needham Reiterates Hold on Lexicon Pharmaceuticalsto Hold
Needham analyst Joseph Stringer reiterates Lexicon Pharmaceuticals (NASDAQ:LXRX) from Hold to Hold.
03-07 20:04
莱斯康制药盘中异动 下午盘快速上涨5.59%报1.70美元
北京时间2024年10月05日03时05分，莱斯康制药（LXRX.us）股票出现异动，股价快速拉升5.59%。截至发稿，该股报1.70美元/股，成交量198.697万股，换手率0.55%，振幅4.35%。 最近的财报数据显示，该股实现营业收入1.65百万美元，净利润-53.43百万美元，每股收益-0.17美元，毛利1.34百万美元，市盈率-2.16倍。 机构评级方面，在所有6家参与评级的机构中，67%的券商给予买入建议，33%的券商给予持有建议，无券商给予卖出建议。 莱斯康制药股票所在的生物技术行业中，整体涨幅为0.06%。其相关个股中，Entero Therapeutics Inc.、Lex...
2024-10-05 03:05
HC Wainwright & Co. Reiterates Buy on Lexicon Pharmaceuticals, Maintains $10 Price Target
HC Wainwright & Co. analyst Joseph Pantginis reiterates Lexicon Pharmaceuticals (NASDAQ:LXRX) with a Buy and maintains $10 price target.
2024-09-11 18:13
The Analyst Verdict: Lexicon Pharmaceuticals In The Eyes Of 8 Experts
In the preceding three months, 8 analysts have released ratings for Lexicon Pharmaceuticals (NASDAQ:LXRX), presenting a wide array of perspectives from bullish to bearish. The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them t...
2024-09-04 03:00
Lexicon Pharmaceuticals' New Secondary Analysis Of Phase 3 Data Demonstrates That INPEFA Benefited Heart Failure Patients Regardless Of Diabetes Duration
Results showed reductions in heart attack, stroke and heart failure events in all patients with even greater benefit for heart failure events among patients with longer diabetes duration New analysis further differentiates INPEFA among SGLT inhibitors THE WOODLANDS, Texas, Sept. 03, 2024 (GLOBE NEWS...
2024-09-03 20:20
Lexicon Pharmaceuticals Says FDA to Hold Meeting in October to Review Zynquista for Type 1 Diabetes, CKD
08:30 AM EDT, 08/21/2024 (MT Newswires) -- Lexicon Pharmaceuticals (LXRX) said Wednesday that the US Food and Drug Administration is expected to hold an Endocrinologic and Metabolic Drugs Advisory Committee meeting on Oct. 31 to review Zynquista for use with insulin in type 1 diabetes and chronic ki...
2024-08-21 20:30
